ArticleBioactive materials2026
Bioengineered apoptotic vesicles overcome energy crisis in bone regeneration through mitochondrial metabolic activation.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Temporal-responsive hydrogels reprogramming energy metabolic pathway in the bone-angiogenic cascade for diabetic bone regeneration.Materials today. Bio · 2026Article
- Aptamer-functionalized tetrahedral framework nucleic acid delivery of siBhlhe22 for repairing osteoporotic bone defects via dual modulation of PI3K-Akt signaling and purine metabolism.Journal of nanobiotechnology · 2026Article
- Review
- Early-apoptotic membrane engineering of M2 macrophage-derived nanovesicles enables osteoimmunomodulatory bone repair.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone regeneration faces dual challenges of insufficient energy supply and oxidative stress, while both energy provision and reactive oxygen species levels are mitochondrially regulated and tend to increase or decrease synchronously. Conventional biomaterials fail to reconcile the high ATP demands of osteogenesis with mitochondrial dysfunction. Here, we present laponite-primed apoptotic vesicles (L@Apo) derived from bone marrow mesenchymal stem cells (BMSCs), engineered to address this bioenergetic crisis through dual-pathway mitochondrial regulation. L@Apo integrates more mitochondrial components and bioactive factors with cargo delivery to activate PINK1/Parkin-mediated mitophagy, selectively eliminating dysfunctional mitochondria while initiating biogenesis to replenish energetic capacity. Concurrent PI3K-/AKTsignaling drives metabolic rewiring, amplifying both glycolysis and oxidative phosphorylation to meet mineralization demands. A thiol-ene hydrogel (L@Apo-G/P) ensures sustained vesicle release, preserving mitochondrial integrity and bioactivity. In vitro, L@Apo promotes osteogenic differentiation, angiogenesis, and anti-inflammatory macrophage polarization while mitigating oxidative damage. In vivo, L@Apo-G/P achieves robust bone regeneration in rat femoral defects, surpassing conventional strategies in structural and functional restoration. This biomaterial platform enhances energy metabolism and reduces oxidative damage through programmable mitochondrial reprogramming, establishing a viable strategy for regenerating tissues with high metabolic demands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.